Beta Bionics, Inc. (BBNX)

NGM – Real vaqt narxi. Valyuta: USD

16.82

+0.91 (5.72%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

16.82

-0.00 (-0.00%)

Bozordan keyin: Jun 26, 2026, 4:31 PM EDT

15.06.2026

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BBNX--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics. Beta Bionics Investors: Suffered Losses? Contact Johnson Fist.

12.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

11.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

09.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

08.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 5, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

05.06.2026

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

05.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Videolar

No Data

There is no data to display

Press-relizlar

15.06.2026

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

12.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

11.06.2026

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

09.06.2026

Beta Bionics, Inc. (BBNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beta Bionics, Inc. (BBNX)

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Videolar

No Data

Press-relizlar

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Videolar

No Data

Press-relizlar

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Search stocks

Beta Bionics, Inc. (BBNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beta Bionics, Inc. (BBNX)

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Videolar

No Data

Press-relizlar

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Videolar

No Data

Press-relizlar

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth